Avalo CMO awarded 43,500 AVTX shares
Avalo Therapeutics, Inc. reported that its Chief Medical Officer, Mittie Doyle, acquired 43,500 shares of Common Stock through a compensation-related award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. reported that its Chief Medical Officer, Mittie Doyle, acquired 43,500 shares of Common Stock through a compensation-related award. The transaction was coded as a grant or award, with a price per share of $0.0000, indicating no cash purchase.
Following this award, Doyle directly holds 47,122 shares of Avalo Therapeutics common stock. The award relates to performance stock units granted on August 19, 2025, which will fully vest on August 19, 2028 if specified performance goals remain achieved and Doyle continues in service through that vesting date.
Insider Trade Summary
Grant/Award: 43,500 shares
Grant/Award
1 txn
Insider
Doyle Mittie
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 43,500 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 47,122 shares (Direct)
Footnotes (1)
- F1. Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Shares granted: 43,500 shares
Price per share: $0.0000 per share
Shares owned after: 47,122 shares
+3 more
6 metrics
Shares granted
43,500 shares
Common Stock grant/award on May 21, 2026
Price per share
$0.0000 per share
Recorded transaction price for grant
Shares owned after
47,122 shares
Direct holdings following the transaction
PSU grant date
August 19, 2025
Date performance stock units were granted
Performance certification date
May 21, 2026
Compensation Committee certified performance goals
Vesting date
August 19, 2028
PSUs scheduled to fully vest, subject to service
Key Terms
performance stock units, contingent right, performance goals, Compensation Committee, +1 more
5 terms
performance stock units financial
"Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025."
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
contingent right financial
"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals."
performance goals financial
"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals."
Performance goals are specific, measurable targets a company sets for financial results, operational milestones, or individual roles—examples include revenue, profit, production levels, or completion of a project. They matter to investors because meeting or missing these targets influences management pay, future forecasts, deal-related payments and market confidence; think of them as a scoreboard that helps outsiders judge whether the business is performing as promised.
Compensation Committee financial
"On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals."
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
vest financial
"As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Avalo Therapeutics (AVTX) disclose for Mittie Doyle?
Avalo Therapeutics disclosed that Chief Medical Officer Mittie Doyle acquired 43,500 shares of Common Stock via a compensation-related grant. The award was recorded at a price of $0.0000 per share, indicating it was not an open-market purchase but part of her equity compensation.
What are the terms of the performance stock units reported for Avalo Therapeutics (AVTX)?
The performance stock units were granted on August 19, 2025, each representing a right to one share of common stock. On May 21, 2026, the Compensation Committee certified achievement of performance goals, and the related shares are set to fully vest on August 19, 2028, contingent on continued service.
Was the Avalo Therapeutics (AVTX) insider transaction a market purchase or a grant?
The transaction was a grant or award, not a market purchase. It is coded as a grant acquisition with a transaction price of $0.0000 per share, indicating Doyle received the shares as part of equity compensation rather than buying them in the open market.
When will the reported Avalo Therapeutics (AVTX) performance stock units fully vest?
The performance stock units associated with the 43,500 shares will fully vest on August 19, 2028. Vesting is contingent on the previously certified performance goals and Mittie Doyle’s continued service with Avalo Therapeutics through that vesting date, as described in the footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
